Select your country or region to view content specific to your country.
Jan 13, 2022
Seegene Inc. (KQ 096530), South Korea’s leading molecular diagnostics (MDx) company, today, unveiled its blueprint for the future during a presentation at the 40th annual J.P. Morgan Healthcare virtual Conference. Dr. Jong-Yoon Chun, CEO of Seegene, proposed three strategic solutions that induce the world ‘back to normal’ against the COVID-19 pandemic. Along with three solutions, he also introduced the company’s automated, AI-enabled platform with a standard development tool that will empower users to easily develop their own diagnostic assays.
Three solutions for ‘back to normal’
In preparation for returning to normal in 2022, Dr. Chun outlined three solutions. △First, it starts with Seegene’s on-site screening solution for mass testing with its fully automated MDx system at various facilities including schools, airports, workplaces, and others. It provides a short turnaround time, economic price, and improved accuracy even for asymptomatic cases, which cannot be detected by rapid antigen tests. △The second solution is Seegene’s centralized screening system, with its newly developed diagnostic test that can multiply the test capacity without additional instrument investments in the laboratories. △The third solution is syndromic testing for patients with respiratory symptoms. Seegene had already introduced Allplex™ RV Master Assay that can simultaneously differentiate ten targets including COVID-19, Flu, and common respiratory viruses. This assay is the key to open a path towards normalcy as it identifies the exact cause of respiratory symptoms.
Strategic shift to a MDx platform company
During the presentation, Dr. Chun unveiled Seegene’s strategic shift as a molecular diagnostics platform company, introducing Seegene’s MDx platform for assay development. Until now, commercial MDx development has been a labor-intensive manual process requiring highly skilled researchers and significant resources. “Our digitalized open development platform will overcome the limitations of the current paradigm of MDx development processes by allowing users to rapidly design and efficiently develop their own diagnostic assays”, said Dr. Chun. “We are pleased to provide our technologies, software and know-how to support rapid and standardized assay development which will eventually help accelerate the use of MDx in our daily lives.”
Seegene’s MDx platform integrates proprietary technologies and development know-how that Seegene has developed over the last two decades, with artificial intelligence (AI)-based automated design system. This platform allows platform users, regardless of knowledge and experience in MDx, to develop high multiplex real-time PCR assays, which will eventually fulfill unmet testing needs at a local level.
Finally, Dr. Chun stated the vision that Seegene stepped ahead to a new horizon by evolving to MDx platform company. Through all these efforts, Seegene will ultimately bring MDx into our daily life.
The full video of the CEO’s remarks will be available after the event at www.seegene.com/ir_event
- Seegene to export COVID-19 test that detects COVID-19 and Omicron along with its Master Assay that distinguishes between COVID-19 and other respiratory viruses Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today that it has delivered over five mil...
- On December 29, Seegene to deliver Allplex™ SARS-CoV-2 Master Assay that can preemptively detect the Omicron variant at the primary screening stage- Earlier this month, the company has hired a private plane to deliver 2.8 million COVID-19 diagnostic tests to European countries including Italy,...